Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Rivastigmine Action Pathway (new)
Homo sapiens
Drug Action Pathway
Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90.
References
Rivastigmine Pathway (new) References
Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25. doi: 10.2174/1389557023406638.
Pubmed: 12369954
Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8. doi: 10.1136/bmj.318.7184.633.
Pubmed: 10066203
Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90. doi: 10.1016/s0149-2918(04)90172-5.
Pubmed: 15336465
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings